Lung Cancer News

Patients with early-stage non–small cell lung cancer, particularly those whose tumors are inoperable and who have limited treatment options, should undergo stereotactic body radiation therapy, according to guidelines from the American Society for Radiation Oncology.

CHICAGO — Manmeet Ahluwalia, MD, a HemOnc Today Editorial Board member and director of the brain metastases research program at Cleveland Clinic, offers background on the developments of medical therapeutics in brain metastases from lung cancer presented at the ASCO Annual Meeting.

More than 3% of patients with kidney cancer that metastasized to the lungs subsequently were found to have primary lung cancer, according to results of a retrospective review published in Clinical Genitourinary Cancer.

CHICAGO — A significant improvement in PFS after first-line therapy allowed more patients with non–small cell lung cancer treated with pembrolizumab than chemotherapy to avoid progressing to second-line therapy, according to updated results of the KEYNOTE-024 trial presented at the ASCO Annual Meeting.

CHICAGO — Nivolumab alone or in combination with ipilimumab demonstrated encouraging activity in patients with relapsed malignant pleural mesothelioma, according to results of the randomized, phase 2 IFCT-1501 MAPS2 trial presented at the ASCO Annual Meeting.

CHICAGO — Nivolumab alone or in combination with ipilimumab demonstrated encouraging activity in patients with relapsed malignant pleural mesothelioma, according to results of the randomized, phase 2 IFCT-1501 MAPS2 trial presented at the ASCO Annual Meeting.

CHICAGO — Nivolumab plus ipilimumab led to durable responses in previously treated patients with small cell lung cancer, according to results from the CheckMate 032 trial presented at the ASCO Annual Meeting.

CHICAGO — Dacomitinib significantly prolonged PFS compared with gefitinib among patients with newly diagnosed, advanced EGFR–positive non–small cell lung cancer, according to randomized phase 3 study results presented at the ASCO Annual Meeting.

CHICAGO — Alectinib stalled cancer growth for a median 15 months longer than crizotinib in patients with ALK–positive non–small cell lung cancer, according to data from the phase 3 ALEX clinical trial presented at ASCO annual meeting.

CHICAGO — Edward S. Kim, MD, chair of the department of solid tumor oncology at Levine Cancer Institute at Carolinas Healthcare System and a HemOnc Today Editorial Board member, discusses various advances within the treatment landscape of lung cancer at the ASCO Annual Meeting.